IOVANCE BIOTHERAPEUTICS, INC.
IOVATicker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Insider trading at IOVANCE BIOTHERAPEUTICS, INC. (IOVA) refers to stock transactions executed by corporate insiders—officers, directors, and shareholders owning more than 10% of the company. Over the past 90 days, 13 insiders have filed 215 transactions totaling $159.7M in trading activity. The most active insider is Wayne P. Rothbaum (Executive), contributing $156.3M across 8 transactions.
IOVANCE BIOTHERAPEUTICS, INC. insiders are currently net buyers of IOVA stock, showing bullish sentiment over the past 90 days. Executives have purchased $159.7M while selling $0, resulting in a positive net flow of $159.7M. This buying activity represents 100% of total transaction volume.
IOVANCE BIOTHERAPEUTICS, INC. has 13 active insiders who have filed SEC Form 4 transactions in the past 90 days. Wayne P. Rothbaum (Executive) leads with 8 transactions totaling $156.3M. Merrill A. Mcpeak (Executive) follows with 11 transactions worth $3.0M. Open-market purchases require insiders to invest their own capital, demonstrating genuine conviction.
The Insider Alignment Score measures the ratio of buying to selling activity on a 0-100 scale. IOVANCE BIOTHERAPEUTICS, INC.'s current score of 100/100 indicates bullish insider sentiment. Scores above 60 suggest insiders are accumulating shares faster than selling, reflecting $159.7M in purchases versus $0 in sales.
The most recent insider transaction occurred on Dec 2, 2025, when G. Vogt Frederick (Executive) disposed of 4,426 shares at $2.14 per share for $9.5K. This appears to be a discretionary trade.
Based on SEC Form 4 filings from the past 90 days, IOVA insider trading sentiment is currently bullish with an Alignment Score of 100/100. The net insider flow of $159.7M reflects accumulation, with 100% of volume being purchases.
SEC Form 4 is the primary disclosure mechanism for insider trading at publicly traded companies like IOVANCE BIOTHERAPEUTICS, INC.. Corporate insiders must file within two business days of any transaction, making it one of the most timely sources of executive sentiment. At IOVA, we track all Form 4 filings—currently showing 215 transactions from 13 insiders over 90 days.
A 10b5-1 plan allows IOVANCE BIOTHERAPEUTICS, INC. executives to pre-schedule stock sales when they don't possess material non-public information. At IOVA, approximately 0% of recent transactions are 10b5-1 trades. Most trading activity at IOVA appears discretionary, making insider signals more meaningful.
You can monitor IOVANCE BIOTHERAPEUTICS, INC. (IOVA) insider trading activity on this page, which updates within hours of new SEC Form 4 filings. We track all 13 active insiders and provide real-time transaction feeds, the Alignment Score, 10b5-1 vs. discretionary breakdowns, and direct links to SEC EDGAR filings.
Insider trading at IOVANCE BIOTHERAPEUTICS, INC. (IOVA) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of shares. These individuals must report trades to the SEC within two business days. Currently, 13 insiders are actively trading IOVA stock, having executed 215 transactions in the past 90 days. The most active insider is Wayne P. Rothbaum (Executive), with 8 transactions totaling $156.3M.
Our Alignment Score measures the ratio of insider buying to selling on a scale of 0-100. A score above 70 indicates strong bullish sentiment, while below 30 suggests bearish activity. IOVANCE BIOTHERAPEUTICS, INC.'s current score of 100/100 indicates strong bullish sentiment with executives accumulating shares. This is calculated from $159.7M in purchases versus $0 in sales over 90 days, resulting in a net flow of $159.7M.
SEC Form 4 filings are mandatory reports that IOVANCE BIOTHERAPEUTICS, INC. insiders must submit within 2 business days. Each filing includes the insider's name, relationship, transaction type, shares, and price. Transaction codes: P (purchase), S (sale), A (award), M (option exercise), G (gift). At IOVA, the most common type is "M" with 32 occurrences. The most recent Form 4 was filed on Dec 2, 2025 by G. Vogt Frederick.
Rule 10b5-1 allows corporate insiders to establish pre-scheduled trading plans when they don't possess material non-public information. At IOVANCE BIOTHERAPEUTICS, INC., approximately 0% of recent transactions are executed under 10b5-1 plans, while 100% appear to be discretionary trades. The low percentage means most insider activity at IOVA represents discretionary decisions with more informational value.
Track every insider move.
Before the market reacts.
Set alerts for IOVANCE BIOTHERAPEUTICS, INC. and 40,000+ other insiders.